Filing Details
- Accession Number:
- 0001209191-23-049840
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-09-18 20:12:03
- Reporting Period:
- 2023-09-15
- Accepted Time:
- 2023-09-18 20:12:03
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1231457 | Genelux Corp | GNLX | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1939103 | John Thomas | C/O Genelux Corporation 2625 Townsgate Road, Suite 230 Westlake Village CA 91361 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2023-09-15 | 2,245 | $21.67 | 480,215 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-09-15 | 1,088 | $22.38 | 479,127 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-09-18 | 3,334 | $24.99 | 475,793 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023.
- The weighted average sale price for the transaction reported was $21.667, and the range of prices were between $21.17 and $22.15. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- The weighted average sale price for the transaction reported was $22.3838, and the range of prices were between $22.19 and $22.75. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Billionaire Hedge Funds
